About Novo Nordisk Global

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk has production facilities in 6 countries, employs more than 23,600 full-time employees in 79 countries, and markets its products in 180 countries.

For Novo Nordisk global, please visit www.novonordisk.com.

Novo Nordisk in China

Since the establishment of Novo Nordisk (China) Pharmaceuticals Co., Ltd. in 1994, the company's presence in China has grown dramatically. And company is able to supply its innovative products and services to patients across the whole of China. The company will employ over 1,000 people in China by the end of 2007.
Novo Nordisk was the first biotech company to establish a R&D center in China. Ongoing investments in our manufacturing plant in Tianjin are developing. Novo Nordisk China, as a strategic manufacturing site for our company is able to supply both the local market as well as to export to other countries in the region.

For Novo Nordisk China, please visit www.novonordisk.com.cn.

Novo Nordisk Tianjin Plant (Hereinafter NNTP)

Novo Nordisk Tianjin Plant (Hereinafter NNTP) rented production room to began production activity in Tianjin city at the end of year 1996. With the development of business and expansion of scope, production room rented can not meet the requirement of production. So in the year of 2001, NNCP decided to buy 40 thousand kilometers lands in Tianjin Economic-Technological Area (TEDA) to build a new plant comply with GMP certificate. The first phrase invested RMB 35 millions to build a plant around 4000 square meters building which include production room, ambient warehouse, cold storage, lab area, archiving room, dining room and office area. On August 13 2003, inauguration ceremony for new plant was formally celebrated and TEDA new pant formally launched into use from now on.

Vice President totally responsible for NNTP and there are include production function, quality function, facility function, administrative function as well. From beginning to now, NNTP organize personnel training and produce products always strictly abide by requirement from Novo Nordisk A/S and Chinese GMP certificate. NNTP invested world advanced automatic production and package technical machines and System of Quality Assurance and Quality Control. From whole production process, validation for equipment and supplier audit all abide by entire international Quality Assurance System. NNTP in TEDA will be finally developed and grown into strategic production base of Novo Nordisk in Asian Pacific Area.

NNTP Organizational-Chart

Our Product